What the trial was testing
The trial enrolled 40 patients with kidney cancer. The study was sponsored by Case Comprehensive Cancer Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Half of patients stayed stable or improved for 9 months on this personalized treatment approach.
The Lancet. Oncology · 2019 · NCT02579811
These findings — that half of patients kept their kidney cancer from getting worse for at least 9 months — were published in the The Lancet. Oncology and represent the headline result of the study.
Researchers tracked outcomes across 40 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with kidney cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If your kidney cancer got worse after immunotherapy, this pill might help. Doctors adjusted the dose based on side effects like fatigue and high blood pressure. This was a mid-stage study and the pill is FDA-approved for kidney cancer, so talk to your oncologist about whether it's right for you after immunotherapy.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open kidney cancer trials
Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage
Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for T1a renal cell carcinoma (RCC) in a randomized clinical trial in single center. The investigators want to explore this technique to robotic surgery and add suture-less technique to T1 RCC patients in randomized clinical trial.
Rein 3D PRINT MECHANICS
The goal of this innovative project is to evaluate the correspondence between several imaging modalities for characterizing the elasticity of healthy and pathological renal tissue which could help improve the realism of 3D prints used by urological surgeons and allow the identification of new, complementary imaging biomarkers. The main objective is to develop a predictive model of the biomechanical properties of normal and pathological kidney tissue, as assessed by the reference method (Magnetic Resonance (MR)-elastography).